Enhancing Immune Response in Mesothelioma via Immunogenic Cell Death – The Babak Lab
The Babak Lab shared a post on LinkedIn:
“Scientific Wednesdays: Exciting News from The Babak Lab!
We are thrilled to announce the publication of our latest article, “Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumours,” in JACS!
Malignant pleural mesothelioma (MPM) is a challenging cancer with limited treatment options, and our work focuses on harnessing the power of immunogenic cell death (ICD) to boost the immune system’s ability to fight these tumours. In this study, we synthesised and characterised 35 novel cyclometalated Au(III) complexes, 25 of which were previously unreported. These compounds demonstrated remarkable potential in inducing phagocytosis and ICD in immunologically “cold” MPM cells.
Key highlights:
We identified complex 2G as a true ICD inducer, eliciting a long-lasting immune response in vaccinated mice. In immunocompetent BALB/c mice, seven of the eight mice immunized with 2G remained tumor-free for 164 days (5.5 months), and four of the eight mice stayed tumor-free for an impressive 210 days (7 months).
Complex 1C showed selective activation of calreticulin in tumours, offering unique insights into necrosis-driven ICD mechanisms.
Our findings provide a predictive framework for ICD effects in structurally similar metal complexes, paving the way for future therapeutic innovations.
This work wouldn’t have been possible without the incredible efforts of Meng Rui Chang, Egor Matnurov, Jemma Arakelyan, Ho-Jung Choe, Andy Wu, Maria (Masha) Babak, Wee Han Ang, Walter Berger and other collaborators.
Check out the full article here.”
Maria (Masha) Babak, Head of The Babak Lab, added a comment:
” I’m incredibly proud to share this work led by our group in collaboration with Profs. Wee Han Ang and Walter Berger!
Our latest publication, ‘Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors’ in JACS, showcases the remarkable potential of novel Au(III) complexes to induce long-lasting antitumor immunity. It is a true testament to the power of teamwork.
Huge congratulations to everyone involved! Let’s keep pushing the boundaries of cancer immunotherapy.”
Jemma Arakelyan, CEO at the Institute of Cancer and Crisis, also added a comment:
“If someone had told me four years ago that I would have a paper in JACS, I would have been skeptical. And here we are – JACS it is!
Check out the full article here.
Thanks to my mentor Maria (Masha) Babak and all co-authors Ho-Jung Choe, Andy Wu, Egor Matnurov who made this possible!”
Authors: Meng Rui Chang et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023